Mercado mundial de la fascioliasis: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado de la fascioliasis

Se espera que el mercado mundial de fascioliasis sea testigo de un crecimiento significativo durante el período de pronóstico. Según la OMS, la fascioliasis se ha observado en más de 75 naciones en todo el mundo con una población mundial infectada generalizada de 2,4 millones. Las áreas más afectadas incluyen América del Sur, Asia Oriental y el Sudeste Asiático. La higiene y el saneamiento comprometidos son las principales razones de las infecciones. Los síntomas de esta enfermedad son principalmente visibles entre las 9 y 11 semanas del inicio de las infecciones. El diagnóstico incluye recuento de eosinófilos, tomografías computarizadas y ecografías. COVID-19 también tuvo un impacto importante en el crecimiento del mercado.

Data Bridge Market Research analiza la tasa de crecimiento del mercado global de fascioliasis en el período de pronóstico 2022-2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado seleccionado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología de pacientes, análisis de cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de la fascioliasis

Definición de mercado

Fascioliasis, also known as liver fluke infestation, is a sub-group of neglected tropical disease defined as parasitic flatworms infections caused by fasciola hepatica. The typical signs and symptoms of fascioliasis are nausea, irregular episodes of fever, abdominal pain, diarrhea and eosinophilia. Individuals infected with this infection mostly don’t show any symptoms, and sometimes symptoms arise associated with the biliary system. In rare cases, long-term complications can also develop

Global Fascioliasis Market Dynamics

Drivers

• Government Initiatives  

The government has numerous supportive schemes along with WHO to increase awareness of treatments, subsidized medicines and reimbursement policies. Government has active funding aids and programs to boost the merging drug manufacturers for fascioliasis treatment. This boosts the market growth.

• High Prevalence of Liver Fluke Infection

According to the Centers for Disease Control and Prevention (CDC), fascioliasis occurs in many areas of the world. Furthermore, fascioliasis is more prevalent in animals than in people. The number of infected people is thought to exceed two million worldwide. In addition, according to the study published in The American Journal of Tropical Medicine and Hygiene, the occurrence of 2.6 million infected and 91 million at risk of developing an infection, worldwide. This boosts the market growth.

Opportunities

• Increased Clinical Trials and Development

The increasing clinical trials and drug developmental processes are creating much opportunities for the market growth. For instance, Triclabendazole is a benzimidazole compound used regularly in veterinary practice to treat fascioliasis. In 1997, after several clinical trials using triclabendazole to treat fascioliasis, the WHO recommended the drug be placed on the essential drugs list.Thus, these factors are essential for the market growth.

• Increasing Demand for Retail Pharmacies

The rise in the number of drugs for fascioliasis being delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Adverse Effects of Fascioliasis Treatment drugs

Severe adverse effects associated with the fascioliasis treatment drugs are expected to hamper the market growth. Effects related to Nitazoxanide such as nausea, discoloured urine, headache, stomach ache, then effects of Triclabendazole such as heavy sweating, dizziness, nausea, hives, itching hamper the growth of the market.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth. Although drug manufactures are thinking to reduce the cost of medicines such as Triclabendazole. Furthermore, development of more effective and safer medications such as Nitazoxanide, niclofolan emetine, chloroquine and heptachlor-para-xylol are under the process after the recommendation by WHO.

This global fascioliasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global fascioliasis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Fascioliasis Market

COVID-19 pandemic has shaken the market in a big way. Several countries, such as China, the major global supplier of active pharmaceutical ingredients and chemicals, were initially infected by the virus. This has undesirably impacted the fascioliasis treatment market. Although, the global fascioliasis treatment market is anticipated to pace with the high growth trend with the restoration of normal situation. People from across the globe are increasing focus on strengthening their immunity because of the pandemic. As proteins are considered one of the significant ingredients leading to good health of an individual, the demand for high-quality milk and protein products has been increased. Thus, the awareness about various infections is also on the roll. All these factors contribute to the market size growth in the post pandemic era.

Global Fascioliasis Market Scope

The global fascioliasis market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Triclabendazole
• Nitazoxanide
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Fascioliasis Market Regional Analysis/Insights

The global fascioliasis market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

Los principales países cubiertos en el informe del mercado global de fascioliasis  son EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de América del Sur como parte de América del Sur.

Asia-Pacífico ha sido testigo de un crecimiento positivo para el mercado mundial de fascioliasis durante el período previsto debido a la alta adopción de medicamentos contra la fascioliasis, la dependencia del ganado como ocupación y el mayor nivel de concienciación de los pacientes, así como la alta prevalencia de la leishmaniasis.

América del Norte domina el mercado debido a la presencia de una infraestructura de atención médica refinada.

La sección de países del informe también proporciona factores de impacto individuales en el mercado y cambios en la regulación del mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Además, se consideran la presencia y disponibilidad de marcas globales y los desafíos que enfrentan debido a la gran o escasa competencia de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales, al tiempo que se proporciona un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado global de la fascioliasis

El panorama competitivo del mercado global de fascioliasis proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado global de fascioliasis.

Los actores clave que operan en el mercado global de la fascioliasis incluyen:

• Emcure Pharmaceuticals Limited (India)
• Cipla Inc. (Estados Unidos)
• Bausch Health Companies Inc. (Canadá)
• Johnson & Johnson Private Limited (EE. UU.),
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Sun Limited (India)
• Aurobindo Pharma (India)
• Abbvie Inc (Estados Unidos)
• Melinta Therapeutics, LLC (Estados Unidos)
• Janssen Global Services, LLC (Estados Unidos)
• Norbrook (Reino Unido)
• Ciencias de la vida Procyon (India)

SKU-54220